Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 13.86% is 15892% above its 5-year average of 0.09%, near the high end of its 5-year range (-24.57%–14.38%).
2.98% below its 12-month average of 14.29%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 4.25%.
RETURN ON ASSETS (ROA)
13.86%
RETURN ON ASSETS (ROA) AVG TTM
14.29%
RETURN ON ASSETS (ROA) AVG 3Y
9.48%
RETURN ON ASSETS (ROA) AVG 5Y
0.09%
RETURN ON ASSETS (ROA) AVG 10Y
-41.90%
RETURN ON ASSETS (ROA) AVG 15Y
-44.53%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-2.98%
CURRENT VS 3Y AVG
+46.13%
CURRENT VS 5Y AVG
+15892.31%
CURRENT VS 10Y AVG
+133.08%
CURRENT VS 15Y AVG
+131.13%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+142.99%
vs the sector median at left
Puma Biotechnology, Inc.
Market Cap
$483.54M
Return on Assets (ROA)
13.86%
TTM Avg
14.29%
3Y Avg
9.48%
5Y Avg
0.09%
Market Cap
$486.01M
Return on Assets (ROA)
-13.84%
TTM Avg
-22.27%
3Y Avg
-29.75%
5Y Avg
-35.86%
Market Cap
$475.91M
Return on Assets (ROA)
-22.99%
TTM Avg
-20.77%
3Y Avg
-18.00%
5Y Avg
-22.63%
Market Cap
$472.23M
Return on Assets (ROA)
-8.14%
TTM Avg
-30.20%
3Y Avg
-72.84%
5Y Avg
-64.85%
Market Cap
$471.65M
Return on Assets (ROA)
1.38%
TTM Avg
-14.74%
3Y Avg
-19.98%
5Y Avg
-18.10%
Market Cap
$471.57M
Return on Assets (ROA)
-3.31%
TTM Avg
-8.72%
3Y Avg
-14.01%
5Y Avg
-17.66%
Market Cap
$469.12M
Return on Assets (ROA)
-17.49%
TTM Avg
-19.59%
3Y Avg
-24.74%
5Y Avg
-16.53%
Market Cap
$498.52M
Return on Assets (ROA)
-32.24%
TTM Avg
-55.64%
3Y Avg
-73.34%
5Y Avg
-69.35%
Market Cap
$467.90M
Return on Assets (ROA)
5.81%
TTM Avg
4.61%
3Y Avg
2.71%
5Y Avg
3.04%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Puma Biotechnology, Inc. (PBYI) | $483.54M | 13.86% | 14.29% | 9.48% | 0.09% |
| Evolus, Inc. (EOLS)vs › | $486.01M | -13.84% | -22.27% | -29.75% | -35.86% |
| Contineum Therapeutics, Inc. (CTNM)vs › | $475.91M | -22.99% | -20.77% | -18.00% | -22.63% |
| Bright Minds Biosciences Inc. (DRUG)vs › | $472.23M | -8.14% | -30.20% | -72.84% | -64.85% |
| Arvinas, Inc. (ARVN)vs › | $471.65M | 1.38% | -14.74% | -19.98% | -18.10% |
| Cerus Corporation (CERS)vs › | $471.57M | -3.31% | -8.72% | -14.01% | -17.66% |
| Alpha Teknova, Inc. (TKNO)vs › | $469.12M | -17.49% | -19.59% | -24.74% | -16.53% |
| Oculis Holding AG (OCS)vs › | $498.52M | -32.24% | -55.64% | -73.34% | -69.35% |
| Kamada Ltd. (KMDA)vs › | $467.90M | 5.81% | 4.61% | 2.71% | 3.04% |
| Tactile Systems Technology, Inc. (TCMD)vs › | $500.52M | 8.89% | 6.33% | 3.95% | 1.76% |
ROA
13.9%
ROE
19.3%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 14.38% |
| 2024-12-31 | 14.19% |
| 2023-12-31 | 9.37% |
| 2022-12-31 | 0.00% |
| 2021-12-31 | -12.85% |
| 2020-12-31 | -24.57% |
| 2019-12-31 | -32.18% |
| 2018-12-31 | -43.84% |
| 2017-12-31 | -176.41% |
| 2016-12-31 | -109.18% |
| 2015-12-31 | -99.77% |
| 2014-12-31 | -87.25% |
| 2013-12-31 | -52.37% |
| 2012-12-31 | -48.98% |
| 2011-12-31 | -18.47% |
| 2010-12-31 | -3458.01% |
| 2009-12-31 | -699.17% |
| 2008-12-31 | -19291.78% |
| 2007-12-31 | -1072.71% |
